Half-year report · HY
4005.TEDINET S100X029
Period2025-04-01 → 2025-09-30
Filed2025-11-10
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.10T | 2025-04-01 → 2025-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥2.61T | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.24T | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥103.7bn | 2025-04-01 → 2025-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥121.2bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥87.9bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥58.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | −¥30.5bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥39.7bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥38.6bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | −¥6.5bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥90.9bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥42.7bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | −¥20.3bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥3.36T | at 2025-09-30 | Cons. | Assets IFRS |
| Total assets | ¥3.44T | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥3.72T | at 2024-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥2.18T | at 2025-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥2.37T | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.18T | at 2025-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.07T | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.09T | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.16T | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥958.7bn | at 2025-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥900.8bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥909.8bn | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥161.2bn | at 2025-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥209.8bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥273.4bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥217.4bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥57.7bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥233.0bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥63.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥16.7bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥85.2bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | ¥74.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥114.8bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥300.8bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥75.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥24.26 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥23.59 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥-3.99 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥24.25 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥23.58 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Equity ratio | 28.5% | at 2025-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 26.2% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 24.5% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 62
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-04-01 → 2025-09-30 | ¥47.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-04-01 → 2025-09-30 | ¥22.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥24.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2025-09-30 | ¥3.2bn |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥36.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥36.6bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥16.2bn |
| Advanced Medical Solutionsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥27.5bn |
| Advanced Medical Solutionsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥21.1bn |
| Advanced Medical Solutionsreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥6.4bn |
| Advanced Medical Solutionsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥1.4bn |
| Agro And Life Solutionsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥213.5bn |
| Agro And Life Solutionsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥213.0bn |
| Agro And Life Solutionsreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥504m |
| Agro And Life Solutionsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥11.2bn |
| Essential And Green Materialsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥331.6bn |
| Essential And Green Materialsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥329.1bn |
| Essential And Green Materialsreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥2.4bn |
| Essential And Green Materialsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥18.6bn |
| ICT And Mobility Solutionsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥284.9bn |
| ICT And Mobility Solutionsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥283.5bn |
| ICT And Mobility Solutionsreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥1.5bn |
| ICT And Mobility Solutionsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥33.1bn |
| Sumitomo Pharmareportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥227.1bn |
| Sumitomo Pharmareportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥226.1bn |
| Sumitomo Pharmareportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥1.1bn |
| Sumitomo Pharmareportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥97.3bn |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥1.08T |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥1.07T |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥11.8bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥121.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥85.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥50.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥34.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | ¥19.4bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥45.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥45.1bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥16.3bn |
| Advanced Medical Solutionsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥31.8bn |
| Advanced Medical Solutionsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥26.8bn |
| Advanced Medical Solutionsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥5.0bn |
| Advanced Medical Solutionsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥355m |
| Agro And Life Solutionsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥225.8bn |
| Agro And Life Solutionsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥225.0bn |
| Agro And Life Solutionsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥830m |
| Agro And Life Solutionsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥14.2bn |
| Essential And Green Materialsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥453.8bn |
| Essential And Green Materialsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥450.9bn |
| Essential And Green Materialsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥2.8bn |
| Essential And Green Materialsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥34.8bn |
| ICT And Mobility Solutionsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥309.5bn |
| ICT And Mobility Solutionsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥307.5bn |
| ICT And Mobility Solutionsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥2.0bn |
| ICT And Mobility Solutionsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥43.6bn |
| Sumitomo Pharmareportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥180.4bn |
| Sumitomo Pharmareportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥180.4bn |
| Sumitomo Pharmareportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥47m |
| Sumitomo Pharmareportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.0bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥1.20T |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥1.19T |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥10.7bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥26.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 916
| Item | Context | Value | Unit |
|---|---|---|---|
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都中央区日本橋二丁目７番１号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03(5201)0235 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)執行役員 経理部長 山 内 利 博 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都中央区日本橋二丁目７番１号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03(5201)0235 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)執行役員 経理部長 山 内 利 博 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E00752 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 40050 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)住友化学株式会社 | |
| Filer name in english | FilingDateInstant | SUMITOMO CHEMICAL COMPANY, LIMITED | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2025-04-01 | |
| Current period end date | FilingDateInstant | 2025-09-30 | |
| Type of current period | FilingDateInstant | HY | |
| Current fiscal year end date | FilingDateInstant | 2026-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2024-04-01 | |
| Comparative period end date | FilingDateInstant | 2024-09-30 | |
| Previous fiscal year end date | FilingDateInstant | 2025-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所プライム市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数は100株であります。 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | InterimInstant_No1MajorShareholdersMember | Original text (Japanese)日本マスタートラスト信託銀行株式会社（信託口） | |
| Address major shareholders | InterimInstant_No1MajorShareholdersMember | Original text (Japanese)東京都港区赤坂一丁目８番１号 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |